(BSX) Boston Scientific - Ratings and Ratios
Medical Devices, Stents, Catheters, Implants, Diagnostic Tools
BSX EPS (Earnings per Share)
BSX Revenue
Description: BSX Boston Scientific
Boston Scientific Corporation is a leading global developer, manufacturer, and marketer of medical devices used in various interventional medical specialties. The companys diverse product portfolio is designed to diagnose and treat a range of medical conditions, including gastrointestinal, urological, and neurological disorders, as well as cardiovascular disease.
The companys MedSurg segment offers a range of products, including devices for gastrointestinal and urological conditions, while its Cardiovascular segment provides technologies for diagnosing and treating coronary artery disease, aortic valve conditions, and other cardiac abnormalities. Key products include implantable devices, such as cardioverter and cardiac resynchronization therapy defibrillators, and diagnostic and treatment technologies for peripheral arterial and venous diseases.
From a financial perspective, Boston Scientifics market capitalization is approximately $153.7 billion, with a forward P/E ratio of 35.34, indicating a relatively high valuation. However, the companys return on equity (ROE) is around 9.56%, suggesting a decent level of profitability. To further evaluate the companys performance, key performance indicators (KPIs) such as revenue growth, gross margin, and operating margin should be monitored. For instance, Boston Scientifics revenue growth has been driven by its diversified product portfolio and strategic acquisitions. Its gross margin has also been stable, indicating a strong pricing power and efficient manufacturing operations.
In terms of potential investment opportunities, Boston Scientifics strong product pipeline, diversified revenue streams, and commitment to innovation make it an attractive investment option for those looking to gain exposure to the healthcare sector. However, investors should carefully evaluate the companys valuation, competitive landscape, and regulatory risks before making any investment decisions. Key metrics to watch include the companys quarterly earnings growth, guidance, and updates on its product pipeline and regulatory approvals.
BSX Stock Overview
| Market Cap in USD | 152,191m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 1992-05-18 |
BSX Stock Ratings
| Growth Rating | 89.6% |
| Fundamental | 72.5% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 4.0% |
| Analyst Rating | 4.59 of 5 |
BSX Dividends
Currently no dividends paidBSX Growth Ratios
| Growth Correlation 3m | 36.4% |
| Growth Correlation 12m | 82.3% |
| Growth Correlation 5y | 93.6% |
| CAGR 5y | 34.72% |
| CAGR/Max DD 3y | 2.24 |
| CAGR/Mean DD 3y | 22.16 |
| Sharpe Ratio 12m | 0.44 |
| Alpha | 1.37 |
| Beta | 0.900 |
| Volatility | 21.01% |
| Current Volume | 11735.6k |
| Average Volume 20d | 6062.4k |
| Stop Loss | 96.8 (-3.1%) |
| Signal | -0.78 |
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income (2.50b TTM) > 0 and > 6% of Revenue (6% = 1.11b TTM) |
| FCFTA 0.08 (>2.0%) and ΔFCFTA 3.23pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 10.44% (prev 22.43%; Δ -11.98pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.10 (>3.0%) and CFO 4.29b > Net Income 2.50b (YES >=105%, WARN >=100%) |
| Net Debt (11.49b) to EBITDA (4.71b) ratio: 2.44 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.37 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.49b) change vs 12m ago 0.61% (target <= -2.0% for YES) |
| Gross Margin 63.23% (prev 62.04%; Δ 1.18pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 47.02% (prev 41.04%; Δ 5.98pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 8.51 (EBITDA TTM 4.71b / Interest Expense TTM 399.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.40
| (A) 0.05 = (Total Current Assets 7.12b - Total Current Liabilities 5.19b) / Total Assets 41.56b |
| (B) 0.10 = Retained Earnings (Balance) 4.14b / Total Assets 41.56b |
| (C) 0.09 = EBIT TTM 3.40b / Avg Total Assets 39.33b |
| (D) 0.18 = Book Value of Equity 3.44b / Total Liabilities 18.91b |
| Total Rating: 1.40 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 72.46
| 1. Piotroski 8.0pt = 3.0 |
| 2. FCF Yield 2.03% = 1.01 |
| 3. FCF Margin 17.90% = 4.48 |
| 4. Debt/Equity 0.51 = 2.37 |
| 5. Debt/Ebitda 2.43 = -0.83 |
| 6. ROIC - WACC -0.35% = -0.43 |
| 7. RoE 11.49% = 0.96 |
| 8. Rev. Trend 98.78% = 4.94 |
| 9. Rev. CAGR 18.54% = 2.32 |
| 10. EPS Trend 85.78% = 2.14 |
| 11. EPS CAGR 66.56% = 2.50 |
What is the price of BSX shares?
Over the past week, the price has changed by -5.02%, over one month by -1.38%, over three months by +1.20% and over the past year by +22.99%.
Is Boston Scientific a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BSX is around 119.71 USD . This means that BSX is currently undervalued and has a potential upside of +19.87% (Margin of Safety).
Is BSX a buy, sell or hold?
- Strong Buy: 23
- Buy: 8
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BSX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 124.5 | 24.7% |
| Analysts Target Price | 124.5 | 24.7% |
| ValueRay Target Price | 133.8 | 34% |
Last update: 2025-09-15 04:32
BSX Fundamental Data Overview
CCE Cash And Equivalents = 534.0m USD (last quarter)
P/E Trailing = 61.1369
P/E Forward = 30.581
P/S = 8.2292
P/B = 6.7888
P/EG = 1.5798
Beta = 0.657
Revenue TTM = 18.49b USD
EBIT TTM = 3.40b USD
EBITDA TTM = 4.71b USD
Long Term Debt = 10.98b USD (from longTermDebt, last quarter)
Short Term Debt = 480.0m USD (from shortTermDebt, last quarter)
Debt = 11.46b USD (Calculated: Short Term 480.0m + Long Term 10.98b)
Net Debt = 11.49b USD (from netDebt column, last quarter)
Enterprise Value = 163.12b USD (152.19b + Debt 11.46b - CCE 534.0m)
Interest Coverage Ratio = 8.51 (Ebit TTM 3.40b / Interest Expense TTM 399.0m)
FCF Yield = 2.03% (FCF TTM 3.31b / Enterprise Value 163.12b)
FCF Margin = 17.90% (FCF TTM 3.31b / Revenue TTM 18.49b)
Net Margin = 13.53% (Net Income TTM 2.50b / Revenue TTM 18.49b)
Gross Margin = 63.23% ((Revenue TTM 18.49b - Cost of Revenue TTM 6.80b) / Revenue TTM)
Tobins Q-Ratio = 47.43 (Enterprise Value 163.12b / Book Value Of Equity 3.44b)
Interest Expense / Debt = 0.79% (Interest Expense 90.0m / Debt 11.46b)
Taxrate = 19.11% (436.0m / 2.28b)
NOPAT = 2.75b (EBIT 3.40b * (1 - 19.11%))
Current Ratio = 1.37 (Total Current Assets 7.12b / Total Current Liabilities 5.19b)
Debt / Equity = 0.51 (Debt 11.46b / last Quarter total Stockholder Equity 22.42b)
Debt / EBITDA = 2.43 (Net Debt 11.49b / EBITDA 4.71b)
Debt / FCF = 3.46 (Debt 11.46b / FCF TTM 3.31b)
Total Stockholder Equity = 21.78b (last 4 quarters mean)
RoA = 6.02% (Net Income 2.50b, Total Assets 41.56b )
RoE = 11.49% (Net Income TTM 2.50b / Total Stockholder Equity 21.78b)
RoCE = 10.37% (Ebit 3.40b / (Equity 21.78b + L.T.Debt 10.98b))
RoIC = 8.37% (NOPAT 2.75b / Invested Capital 32.81b)
WACC = 8.72% (E(152.19b)/V(163.65b) * Re(9.33%)) + (D(11.46b)/V(163.65b) * Rd(0.79%) * (1-Tc(0.19)))
Shares Correlation 3-Years: 100.00 | Cagr: 0.33%
Discount Rate = 9.33% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 77.37% ; FCFE base≈2.69b ; Y1≈3.32b ; Y5≈5.66b
Fair Price DCF = 51.45 (DCF Value 76.23b / Shares Outstanding 1.48b; 5y FCF grow 25.0% → 3.0% )
Revenue Correlation: 98.78 | Revenue CAGR: 18.54%
Rev Growth-of-Growth: 5.73
EPS Correlation: 85.78 | EPS CAGR: 66.56%
EPS Growth-of-Growth: -27.02
Additional Sources for BSX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle